Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Commotio cordis…once again: Unusual occurrence in a noncontact sport.

HeartRhythm case reports·2024
Same author

Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy.

Circulation·2023
Same author

Analysis of risk stratification and prevention of sudden death in pediatric patients with hypertrophic cardiomyopathy: Dilemmas and clarity.

Heart rhythm O2·2023
Same author

QRS Fragmentation as a Risk Marker for Sudden Death in Hypertrophic Cardiomyopathy.

JACC. Clinical electrophysiology·2023
Same author

Medical and Legal Determinants of Sports Eligibility for Young Competitive Athletes With Cardiovascular Disease.

Journal of the American College of Cardiology·2023
Same author

Commotio Cordis Returns…When We Least Expected It: Cardiac Arrest in A Professional Football Player.

The American journal of cardiology·2023
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: May 19, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

ハイパートロフィック心筋病変症

Barry J Maron1, Martin S Maron

  • 1The Hypertrophic Cardiomyopathy Centers of Minneapolis Heart Institute Foundation, Minneapolis, MN, USA.

Lancet (London, England)
|August 10, 2012
PubMed
まとめ
この要約は機械生成です。

ハイパルトロフィック心筋病変 (HCM) は,500人に1人に影響する一般的な遺伝性心疾患です. 突然死などのリスクにもかかわらず,効果的な治療法により,多くの診断された人の生活の質と長寿が改善されています.

さらに関連する動画

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

関連する実験動画

Last Updated: May 19, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

科学分野:

  • 心血管医学 心血管医学
  • 遺伝学 遺伝学とは
  • 遺伝性心血管疾患 遺伝性心血管疾患とは

背景:

  • ハイパルトロフィック心筋病 (HCM) は,500人に1人に影響する一般的な遺伝性心血管疾患です.
  • それは,心臓サルコメアタンパク質をコードする遺伝子の1400以上の変異から生じます.
  • HCMは,スポーツ選手を含む若者における突然心臓死の主な原因です.

研究 の 目的:

  • ハイパートロフィック心筋病症の現在の理解をレビューする.
  • 診断基準と利用可能な治療戦略を強調する.
  • 過去50年にわたるHCM経営の変革について議論する.

主な方法:

  • 臨床診断は,エコーカルディオグラフィーまたは心血管MRIによる説明不能の左心房高縮の特定に依存しています.
  • 治療戦略には,埋め込み式 défibrillators,薬,外科的 myectomy,アルコールの隔膜切除,および心房細動の管理が含まれています.
  • 遺伝検査は,明らかな高縮症のない患者を含む突然変異を特定します.

主要な成果:

  • 潜在的重症にもかかわらず,HCMを患っている多くの個人は診断されないままであり,寿命が著しく短縮されることもありません.
  • 急性死亡を予防し,心不全の症状を管理し,脳卒中のリスクを減らすための効果的な治療法があります.
  • 遺伝子の変異があるが,左心房縮がない患者のサブセットは,さらなる研究のための領域を提示します.

結論:

  • ハイパルトロフィック心筋症は,希少で治療が不可能な状態から,管理可能な結果を持つ一般的な遺伝疾患へと進化しました.
  • 現在の管理戦略は,生活の質の向上と長寿の延長のための現実的な展望を提供します.
  • 継続的な研究が必要であり,特に遺伝子の変異があるが,左心房高縮症のない患者に必要である.